Sunnyvale, Calif. – October 05, 2026 -- Applied Intuition, Inc. has partnered with Honda Motor Co., Ltd. to accelerate development of the automaker's next-generation software-defined vehicle (SDV) platform.

Tokyo – October 04, 2026 -- Celaid Therapeutics Inc. has completed the second close of its Series B financing round, raising JPY 400 million (approximately USD 2.6 million) with new backing from Shionogi & Co., Ltd. and Teikoku Ventures, Inc.

Tokyo – October 04, 2026 -- Bloomberg has completed the first fully automated Japanese Government Bond (JGB) Market-on-Close trade, executed through a new workflow aligned to BB3P (Hikene Trading), the reference rate for JGB closing prices.

Tokyo – October 04, 2026 -- TIER IV, the developer of open-source autonomous driving software Autoware, has been selected by Japan's Ministry of Economy, Trade and Industry for a grant program backing collaborative technology initiatives in the Global South, under which it will conduct autonomous bus field operational tests (FOTs) in Saudi Arabia.

Palo Alto – October 01, 2026 -- PaleBlueDot AI has closed a $200 million Series C financing round led by ComputeCore, valuing the Silicon Valley-based AI infrastructure provider at $3.2 billion.

Funding round follows January's $150 million Series B

The new round builds on a $150 million Series B announced in January 2026. Existing shareholder B Capital participated again alongside other global investors.

San Francisco – October 01, 2026 -- Linux Foundation Networking (LFN) has released the initial session lineup for ONE Summit Japan 2026, set for Dec. 10-11 in Tokyo alongside Open Source Summit Japan.

Paramus, N.J. – October 01, 2026 -- NS Pharma, Inc. reported 5-year efficacy and safety data showing its investigational therapy brogidirsen maintained or improved motor function in Duchenne muscular dystrophy (DMD) patients amenable to exon 44 skipping, with zero treatment discontinuations across the study period.

Dallas – October 01, 2026 -- Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has accepted and granted priority review to Nanoscope Therapeutics' New Drug Application for MOGENRY (sonpiretigene isteparvovec, MCO-010), an optogenetic gene therapy for inherited retinal dystrophies (IRDs). If approved by the Ministry of Health, Labour and Welfare, MOGENRY would become the first disease-agnostic treatment available to IRD patients in Japan, a condition caused by mutations across more than 250 genes that leads to progressive photoreceptor loss and blindness.

Tokyo – September 30, 2026 -- TIER IV, the developer behind the open-source autonomous driving software Autoware, has joined Arm Total Design for Physical AI, a move aimed at expanding Autoware's availability across Arm-based system-on-chips and in-vehicle computing platforms.

Columbus, Georgia – September 30, 2026 -- Aflac Incorporated (NYSE: AFL) will release third-quarter 2026 financial results after market close on Wednesday, November 4, 2026.

Earnings materials post same day as market close

The quarterly earnings release and financial supplement will be published on the company's investor relations site, investors.aflac.com, alongside a financial update video from Senior Executive Vice President and Chief Financial Officer Max K. Brodén.